Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a medical device company that focuses on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions using superficial radiotherapy (SRT and IG-SRT). The SRTS news page on Stock Titan aggregates company announcements, press releases and market updates so readers can follow how Sensus’ technology, reimbursement environment and commercial activities evolve over time.
Recent news highlights include recognition of Sensus Healthcare as a global pioneer in non-invasive treatments for skin cancer and keloids, updates on clinical evidence for its SRT systems, and developments in reimbursement policy. The company has reported that the Centers for Medicare & Medicaid Services established dedicated CPT codes specific to superficial radiotherapy for non-melanoma skin cancer, which Sensus describes as a pivotal moment for its platform and strategy. News items also cover growth in treatment volumes under its Fair Deal Agreement program and shipments of SRT systems to both U.S. and international customers.
Investors and healthcare professionals can use this news feed to track quarterly financial results, board and governance changes, conference participation, and recognition such as Sensus Healthcare’s inclusion in TIME’s America’s Growth Leaders of 2026 ranking. Clinical and scientific updates, including published studies on the use of SRT for keloids, provide additional context on how the company’s technology is being used in practice.
By reviewing the SRTS news stream regularly, readers can see how Sensus Healthcare communicates its progress in radiation oncology technology, reimbursement milestones, commercial expansion and clinical validation of its superficial radiotherapy solutions.
Sensus Healthcare (Nasdaq: SRTS) launched Sensus Link, a proprietary cloud-based software and add-on for the SRT-100™ installed base that adds workflow, treatment documentation and operating intelligence.
Sensus Link aims to expand access to advanced operating features, support Fair Deal Agreement and direct-purchase customers, and create a scalable recurring-revenue stream tied to treatment workflows and oversight services. A phased commercial rollout is expected during 2026, subject to commercial terms and customer onboarding.
Sensus Healthcare (Nasdaq: SRTS) launched Sensus Healthcare Financial Services on February 18, 2026 to simplify acquisition of its SRT and IG-SRT systems for dermatology practices with purchase and leasing options.
The program aims to boost conversions, leverage new CPT reimbursement clarity (approximate 300% per-fraction code increase), and lower the breakeven patient threshold to one patient per month, while offering bank-supported leasing subject to customary underwriting.
Sensus Healthcare (Nasdaq: SRTS) reported Q4 2025 revenue of $4.9M and full-year revenue of $27.5M, with a 2025 net loss of $7.7M and Q4 net loss of $3.2M. The company shipped 14 SRT systems in Q4 and 70 for the year, ended 2025 with $22.1M cash and no debt, and recorded 11,411 FDA treatments in 2025.
Critically, new CPT reimbursement codes (effective Jan 1, 2026) increased the SRT delivery rate by ~300% per fraction, which management says provides reimbursement certainty and supports expected sequential revenue growth and full-year profitability in 2026.
Sensus Healthcare (Nasdaq: SRTS) will report fourth quarter and full year 2025 financial results on February 12, 2026. Management will host a conference call at 4:30 p.m. ET to review results, provide a business update and answer questions.
Participants may pre-register to receive dial-in details or join via the provided toll-free numbers and webcast. A telephone replay will be available until March 12, 2026, and an archived webcast will be posted in Investor Relations.
Sensus Healthcare (Nasdaq: SRTS) announced management will meet with healthcare investors January 12–14, 2026 in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. Management highlighted recently established CMS coding validating its superficial radiotherapy for non-melanoma skin cancer, momentum in the Fair Deal Agreement program, and an expanding international footprint. Investors seeking private meetings at the Alliance Advisors IR 22nd Annual Investor Offsite during JPM Week are asked to contact Tirth Patel at tpatel@allianceadvisors.com.
Sensus Healthcare (Nasdaq: SRTS) announced that Larry Biscotti has been appointed to its Board of Directors effective January 7, 2026. The Board now has six directors, including four independent directors.
Mr. Biscotti is president, Imaging for the U.S. and Canada at GE HealthCare and brings 25+ years of executive experience in medical devices, imaging, oncology and radiation therapy. His prior roles include positions at Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Medicine and CTI Molecular Imaging. He holds an MBA from Pepperdine, a BS from Cornell, and completed Harvard Business School’s Program for Leadership Development.
Sensus Healthcare (Nasdaq: SRTS) on November 14, 2025 announced that President Michael Sardano has been named Chief Commercial Officer in a newly created role to lead global sales, marketing and commercial strategy for SRT technologies, Sentinel software and related services.
The expanded role follows a reimbursement milestone from CMS that established CPT codes for SRT and IG-SRT for non-melanoma skin cancer, which the company says has driven increased interest across dermatology and oncology practices. Mr. Sardano will focus on physician adoption, recurring-revenue models and growth in U.S. and international markets.
Sensus Healthcare (Nasdaq: SRTS) announced on November 12, 2025 the appointment of Eric Sachetta to its Board of Directors to fill the vacancy left by the passing of long-serving director Bill McCall. Sachetta is a seasoned financial executive and currently Chief Wealth Services Officer of Sachetta, LLC, where he oversees advisory strategy and wealth management operations since 2022.
He has prior leadership experience founding The E TEAM and authored a personal leadership curriculum. Sachetta holds a B.S. in Corporate Finance & Accounting from Bentley University and professional credentials including CFP, ChFC, TPCP and a Series 65 license. Company leadership said they expect his financial and people-focused experience to support strategic growth and SRT technology expansion.
Sensus Healthcare (NASDAQ: SRTS) reported third quarter 2025 results on November 6, 2025: revenues $6.9M, net loss $0.9M (‑$0.06/share), and Adjusted EBITDA ‑$2.4M. CMS established dedicated CPT coding validating SRT for non‑melanoma skin cancer. The company shipped 16 SRT systems (three to China), reported FDA treatment volume +20% QoQ (+52% vs Q1), and published clinical data on SRT plus punch excision for keloids. Cash was $24.5M at quarter end with no debt and ~100 systems in inventory.
Sensus Healthcare (Nasdaq: SRTS) was named to TIME’s America’s Growth Leaders of 2026 on November 6, 2025, ranking No. 72 among 500 U.S. publicly traded companies. The ranking reflects five-year revenue growth, financial stability, and stock performance. The company highlighted continued commercial momentum, global expansion, and growing adoption of its superficial radiation therapy (SRT and IG-SRT) systems for non-melanoma skin cancer and keloids.
Management emphasized the award as recognition of sustained growth, customer service, and clinical outcomes supporting adoption over the past 15 years.